Last verified: April 2026
The Polling-Politics Disconnect
Iowa polling has shown steady growth in support for cannabis reform. The Iowa Poll (Des Moines Register / Mediacom Iowa Poll, conducted by Selzer & Co.) has tracked the trend over multiple cycles, with majority support for medical cannabis expansion and significant minority support for adult-use legalization.
Yet the legislature has not moved. Gov. Kim Reynolds (R) has signed restrictive hemp regulation (HF 2605, 2024) but no medical-program expansion beyond the modest 2020-2022 changes. Iowa Republican leadership has consistently prioritized other issues, citing federal Schedule I status and law-enforcement concerns about workplace impairment.
Iowa Republican leadership has cited federal Schedule I status, the per se OWI metabolite rule, and workplace-testing complications as the structural reasons for not expanding the medical cannabidiol program or considering decriminalization.
Iowa Senate Republican Caucus, multiple sessions
The Caucus-State Aftermath
Iowa was a presidential caucus state for both parties from 1972 to 2024. The Democratic National Committee moved the New Hampshire and Iowa caucuses from first-in-the-nation status starting in 2024, and the Iowa Republican caucus held its 2024 contest before continuing to lose its preeminent role. The post-caucus political landscape is more locally focused and less subject to the candidate-driven scrutiny that surrounded earlier reform efforts.
Pre-2024, presidential candidates regularly visited Iowa and faced cannabis reform questions. That structural pressure has eased.
Key Legislators
- Gov. Kim Reynolds (R) — took office 2017. Has signed the 2020 expansion (HF 2589, raising THC cap to 4.5g/90 days) and the 2022 expansion (SF 599) but has signaled no interest in adult-use or significant medical expansion.
- Sen. Jack Whitver (R-Ankeny) — Senate Majority Leader. Generally aligned with caucus on cannabis (no expansion).
- Rep. Pat Grassley (R-New Hartford) — House Speaker. Grandson of U.S. Sen. Chuck Grassley.
- Former Sen. Joe Bolkcom (D-Iowa City) — the original medical cannabidiol bill author (SF 2360, 2014). Retired from the Senate in 2022.
- Rep. Bruce Hunter (D-Des Moines) — longtime cannabis reform advocate.
- Rep. Clel Baudler (R, retired) — the 2014 House sponsor who amended the bill to its CBD-only form.
See key legislators for full profiles.
Advocacy Groups
- Iowa NORML — state-level chapter
- ACLU of Iowa — ED Mark Stringer; central focus on the 7.3x racial-disparity statistic
- Iowa Cannabis Patient Network (ICPN) — patient advocacy
- Marijuana Policy Project — Iowa
- Iowa Department of Health and Human Services Office of Medical Cannabidiol — regulator
See advocacy groups.
The 2024 Hemp Act as Bellwether
The most significant cannabis-related legislation Iowa has passed since 2020 was HF 2605 (2024), which restricted rather than expanded access. That direction is consistent with the broader caucus posture: federal Schedule I as the operative reason to avoid expansion, with ⚠️ HF 2605’s passage a signal that legislative output points toward tightening.
2026 Inflection Points
- Trump December 2025 federal Schedule III rescheduling EO — Iowa GOP leaders unconvinced; the “wait for the feds” defense becomes harder to maintain if rescheduling actually finalizes
- November 12, 2026 federal hemp cliff (P.L. 119-37) — tightens Iowa’s already-restrictive HF 2605 framework further
- 2026 General Election — Iowa legislative seats and gubernatorial election
- 2027 General Assembly session — first opportunity for new leadership posture
See 2026 and beyond.
Most Likely 2026–2030 Trajectory
Continued status-quo with no movement absent (a) federal Schedule III rescheduling actually finalizing, (b) a leadership change in the legislature, or (c) a budget shortfall large enough to make cross-river revenue capture politically attractive. The Iowa Republican caucus has shown more willingness to pass restrictive hemp legislation than to expand the medical program.
Explore Reform & Politics
For in-depth cannabis education, dosing guides, safety information, and research summaries, visit our partner site TryCannabis.org